< Back to latest news & events

Knowledge Hub

Coronavirus update: Oral proceedings before Opposition Divisions and Boards of Appeal

August 2020

In view of the ongoing disruptions caused by the spread of Coronavirus (COVID-19), the European Patent Office (EPO) has implemented special measures for arrangement and conduct of oral proceedings. These measures are now updated with respect to oral proceedings before Opposition Divisions and Boards of Appeal. Oral proceedings in examination will continue to be held by videoconference.

Oral proceedings before Opposition Divisions

The EPO has decided to postpone oral proceedings in opposition scheduled until 31 December 2020 (previously until 14 September 2020).

Cases affected are those that have not already been confirmed to take place by videoconference or will be held by videoconference with the parties’ consent under the Pilot Project for oral proceedings. Under the Pilot Project (Article 2 of the Decision of the President of the EPO dated 14 April 2020) oral proceedings before Opposition Divisions may be held by videoconference at the discretion of the Opposition Division and with the agreement of all parties. The parties will be informed about the postponement of oral proceedings in affected cases as soon as possible.

The EPO intends to maintain oral proceedings in opposition which have been scheduled to take place on the premises of the EPO on or after 4 January 2021.

Oral proceedings before Boards of Appeal

The EPO has also decided to discontinue the recently introduced practice of contacting parties to enquire whether they are able to attend oral proceedings before the Boards of Appeal. If parties cannot attend oral proceedings for which they have been summoned, they will now have to request a change of date (Article 15(2) RPBA 2020).

In addition, owing to the need for physical distancing, venues and/or starting times for oral proceedings may be changed without informing parties. As such, changes may take place at short notice, and it is up to the parties to consult the online calendar approximately three days before their oral proceedings to check whether they will take place on the Haar premises or in the Isar building and when exactly they are scheduled to start.

See the official notice here.

This update was prepared by HGF Senior European Patent Attorney Dr Alex Colman. If you would like further advice on this or any other matter, please contact Alex.  Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

Event - 7th January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Read article

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Read article

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

Often Copied, Never Equaled: When Do Everyday Items Become Subject of Copyright?

The  borderline between ‘pure’ works of art and mere utilitarian objects” –  Can iconic, yet everyday products be protected under copyright? The above question was posed by Advocate General in …

Read article

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Read article